Look back at pharma news in the week to February 12, 2021
By Barbara Obstoj-Cardwell. Editor
After various delays, the US Food and Drug Administration finally approved Bristol Myers Squibb’s lisocabtagene maraleucel (liso-cel), now branded Breyanzi, for the treatment of B-cell lymphoma. The FDA also gave the green light to Regeneron Pharmaceutical’s biological cholesterol-lowerer Evkeeza (evinacumab-dgnb). On the research front, shares of KalVista Pharma rocketed more than 140%after it released mid-term data on its hereditary angioedema candidate KVD900. Additionally, Gilead Sciences and Dutch partner Galapagos discontinued the Phase III trial of ziritaxestat, marking another blow to their collaboration.
Some good news for liso-cel at last
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze